Equities research analysts predict that OvaScience Inc (NASDAQ:OVAS) will report earnings per share of ($0.29) for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for OvaScience’s earnings, with the highest EPS estimate coming in at ($0.28) and the lowest estimate coming in at ($0.32). OvaScience posted earnings per share of ($0.64) in the same quarter last year, which suggests a positive year over year growth rate of 54.7%. The company is expected to announce its next quarterly earnings report on Thursday, March 1st.
According to Zacks, analysts expect that OvaScience will report full-year earnings of ($1.48) per share for the current fiscal year, with EPS estimates ranging from ($1.51) to ($1.47). For the next year, analysts expect that the company will report earnings of ($1.11) per share, with EPS estimates ranging from ($1.33) to ($0.92). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow OvaScience.
Several research analysts have recently issued reports on OVAS shares. Zacks Investment Research raised OvaScience from a “hold” rating to a “buy” rating and set a $1.25 price objective for the company in a research note on Wednesday, January 10th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of OvaScience in a research note on Monday, November 6th.
A number of large investors have recently added to or reduced their stakes in the business. Wells Fargo & Company MN increased its position in OvaScience by 28.8% during the 2nd quarter. Wells Fargo & Company MN now owns 164,283 shares of the biotechnology company’s stock valued at $256,000 after purchasing an additional 36,720 shares during the period. Susquehanna International Group LLP increased its position in OvaScience by 87.2% during the 2nd quarter. Susquehanna International Group LLP now owns 112,781 shares of the biotechnology company’s stock valued at $176,000 after purchasing an additional 52,538 shares during the period. Sabby Management LLC increased its position in OvaScience by 20.2% during the 2nd quarter. Sabby Management LLC now owns 509,300 shares of the biotechnology company’s stock valued at $795,000 after purchasing an additional 85,525 shares during the period. Two Sigma Investments LP acquired a new stake in OvaScience during the 4th quarter valued at approximately $342,000. Finally, Broadfin Capital LLC acquired a new stake in OvaScience during the 2nd quarter valued at approximately $429,000. 54.88% of the stock is owned by institutional investors and hedge funds.
OvaScience Company Profile
OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OvaScience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience and related companies with MarketBeat.com's FREE daily email newsletter.